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Stroke is the second leading cause of death and a main cause of disability worldwide.+e majority (approximately 80%) of strokes
are ischemic. Saffron (Crocus sativus L.) has been considered for medicinal purposes since ancient times. Pharmacological effects
of saffron are attributed to the presence of crocin, crocetin, picrocrocin, and safranal. In the present review, we summarized the
reported neuroprotective effects of saffron and its active constituents against cerebral ischemia stroke. Saffron and its components
exert its beneficial effects as an antioxidant, anti-inflammatory, and antiapoptotic agent though inhibition of biochemical,
inflammatory, and oxidative stress markers. Taken together, this review indicates that saffron and its ingredients could be a potent
candidate in the process of new drug production for the treatment of ischemia stroke.
1. Introduction
Stroke is the second leading cause of death and amajor cause
of long-term disability worldwide [1]. Over recent decades,
the burden of stroke has been highly increased in many
regions of the world and, particularly, in developing
countries [2]. Notably, as societies are getting older, the
demand for long-term care for such illnesses is rising [1].
Ischemic stroke accounts for the highest percentage of all
strokes, approximately 80%. +e remaining 20% of strokes
are hemorrhagic in nature [2, 3]. Cerebral ischemic stroke is
the interruption of blood flow to the brain resulting from
blood vessel blockage by vascular thrombus formation [4, 5].
Ischemic stroke contributes to tissue damage, neurological
deficits, impairment of motor function, epilepsy, and
poststroke dementia and may lead to death [6–8]. To date,
the number of efficient curative treatments for ischemic
stroke is limited. Currently, thrombolytic therapy with tissue
plasminogen activator is the most effective treatment, which
must be administered within 4.5 hours from ischemic stroke
onset [9, 10]. Medicinal plants are invaluable source for the
discovery of new therapeutic agents for a wide variety of
human ailments [11–13]. +e complex pathogenesis of
stroke and multifactorial effect of herbal drugs and their
active ingredients may indicate the promising future of
herbal medicine for stroke treatment. Neuroprotective, anti-
inflammatory, antioxidant, antiapoptotic, and vascular
protective properties of herbal drugs are believed to be
Hindawi
Evidence-Based Complementary and Alternative Medicine
Volume 2021, Article ID 6643950, 8 pages
https://doi.org/10.1155/2021/6643950
efficacious in treating stroke [11, 14–16]. Saffron has been
extensively used for many medicinal purposes such as a pain
reliever and expectorant, as well as for treatment of in-
flammation, wounds, and abscesses in folk medicine [17, 18].
Recent studies showed the value of saffron and its com-
ponents in ischemia stroke. +erefore, in the current study,
we aimed to review the anti-ischemic activities of saffron.
Table 1 shows experimental studies assessing the effect of
saffron and its bioactive ingredients on cerebral ischemic
stroke.
2. Research Methodology
A comprehensive search of Embase, PubMed, Scopus, and
Google Scholar databases was carried out. Different relative
keywords including Crocus sativus, safranal, stroke, neu-
roprotection, herbal medicine, and crocin were searched.
+e search included the papers published up to August 2020.
3. Saffron
Saffron is a valuable dietary spice derived from the flowers of
Crocus sativus (Iridaceae). Saffron has been known since a
long time as an herbal medicine [18, 19]. Saffron is now likely
to be such an agent that has aroused physicians’ interest [20].
At present, modern pharmacological investigations have
demonstrated that saffron and its ingredients have a lot of
therapeutic effects such as anticancer [21], antimicrobial
[22], antineuropathic pain [23], hypolipidemic [24], anti-
diabetic [25], antianxiety [26], antitussive [27], antiobesity
[28], antitremor [29], hypotensive [30], anticonvulsant [31],
antidepressant [32], and antiarthritis effects [33]. Also,
gastric ulcer healing [34], memory improvement [35], and
management of metabolic syndrome [36] have been re-
ported for this medicinal plant.
3.1. Bioactive Principles of Saffron. +e main ingredients of
saffron are water, nitrogenous matter, anthocyanins, gly-
cosides, monoterpenes, aldehydes, flavonoids, vitamins
(especially riboflavin: 56–138 μg/g and thiamine: 0.7–4 μg/g),
volatile oil, proteins, amino acids, carbohydrates, minerals,
raw fibers, and gums. Furthermore, picrocrocin (responsible
for the bitter taste) and apocarotenoids ingredients such as
crocetin, crocin (responsible for the color), and safranal
(responsible for odor and aroma) are considered to be the
main bioactive constituents [37, 38]. High-quality saffron
has approximately 30% crocins, 5 to 15% picrocrocin, and
2.5% volatile compounds, including safranal [39].
4. Experimental Studies Conducted on the
Effects of Saffron on Ischemia Stroke
Zhong et al. utilized the ischemic rat model to explore the
neuroprotective effects of saffron on late cerebral ischemia
injuries. Sprague-Dawley rats were subjected to focal cere-
bral ischemia induced by middle cerebral artery occlusion
(MCAO). Rats were then assigned to six groups: sham,
MCAO, Edaravone (as a positive control), and saffron ex-
tract (30, 100, and 300mg/kg for 42 days). Saffron effectively
reduced the levels of IL-6 and IL-1β and expressions of glial
fibrillary acidic protein (GFAP), neurocan, and phosphocan,
quantified by ELISA and Western blot, respectively. It also
reduced neurological problems and spontaneous move-
ments as well as anxiety-like behaviors and cognitive im-
pairment, examined by elevated plus maze (EPM), marble
burying test (MBT), and novel object recognition test
(NORT). Besides, saffron showed anticerebral ischemia
properties by reducing the infarct volume and glial scar
formation [20].
Abdel-Rahman et al. designed a study to examine the
role of vascular endothelial growth factor (VEGF) in the
neuroprotective effect of saffron against cerebral ischemia/
reperfusion injury (IR) in rats. Focal cerebral ischemia was
induced by left MCAO. Wistar rats received only normal
saline or saffron at doses of 100 and 200mg/kg. Saffron was
administrated intraperitoneally three weeks before surgery
and then administered four times (60min before surgery,
during the surgery, and on 1 day and 2 days post-IR). A
significant reduction in the latency to move their bodies and
to fall in animals treated with saffron in relation to the
control group was observed. According to the findings of
this study, reducing oxidative stress and apoptotic proteins
and exertion of vascular protection are among the main
mechanisms mediating the neuroprotective effect of saffron.
Also, the modulation of VEGF by saffron was considered as a
pathway arbitrating its neuroprotective and antiapoptotic
properties [40].
5. Experimental Studies Conducted on the
Effects of Crocin on Ischemia Stroke
In one study, the anti-ischemic effect of crocin in male rats,
which underwent a two-hour right MCAO, was investigated.
Male rats were randomly divided into four groups: the sham-
operated group, the MCAO group, and the crocin groups
that were administrated 50 and 100mg/kg of crocin orally.
+e treatments were applied for seven days, and rats were
operated two h after the last administration. +e results
showed that the infarction areas and the neurological score
decreased in crocin groups. Besides, crocin reduced the level
of autophagy following cerebral ischemia by activating
mTOR, which is a downregulator of autophagy processes.
+e results obtained from in vitro study showed that oxygen-
glucose deprivation/reoxygenation significantly enhanced
the proportion of apoptotic cells. Moreover, transmission
electron microscope images demonstrate that the amount of
autophagosome increased after oxygen-glucose deprivation/
reoxygenation but decreased after treatment with 50 μM
crocin [41].
Huang and Jia examined the neuroprotective effect of
crocin in the mouse model of hypoxic-ischemic encepha-
lopathy. C57BL/6J mice were subjected to left common
carotid artery ligation, and, after one-hour recovery, mice
were treated by either hypothermia, crocin (10mg/kg), or
combined treatment. Results displayed that crocin treatment
alone decreased brain damage and inflammation after
hypoxia-ischemia. Combined treatment of crocin and hy-
pothermia demonstrated increased therapeutic effect
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Table 1: Experimental studies assessing the effect of saffron and its bioactive ingredients on cerebral ischemic stroke.
Product Animal type Stroke model Doseadministration
Duration of
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compared with single treatment, resulting in markedly less
brain injury, decreased oxidative and inflammatory re-
sponses, and improved functional outcome. +eir result
demonstrated the beneficial effect of crocin as a part of
combined therapy to enhance the neuroprotective effect of
hypothermia and reduce hypoxia [42].
+e therapeutic effect of crocin in improving the blood-
brain barrier (BBB) disruption following MCAO was
evaluated. 24-month-old rats randomly received either ve-
hicle (controls) or crocin (10, 20, 40, or 60mg/kg) every
alternate day for two months before ischemia induction. In
the presence of cerebral ischemia, crocin saved the BBB
function. Besides, loss of tight junction complexes, the ac-
tivity of matrix metallopeptidase (MMP), and increased
NADPH oxidase were all attenuated in the crocin-treated
group. +ese findings revealed that the antioxidant capacity
of crocin could ameliorate the ischemia-induced damage
[43].
Another study showed that crocin pretreatment (40mg/
kg for ten days) once daily attenuated apoptosis, probably
mediated by decreasing oxidative stress index and increasing
total antioxidant capacity (TAC) induced by reactive oxygen
species (ROS) generation and inhibiting the protein ex-
pression of HIF-1α, TUNEL, and caspase-3 in a rat global
cerebral IR induced by bilateral common carotid artery
occlusion (BCCAO), followed by 30-minute reperfusion
[44].
Crocin treatment (30, 60, and 120mg/kg) markedly
reduced infarct volume by 64%, 74%, and 73%, respectively,
in a rat model of transient focal cerebral ischemia. Indeed,
Table 1: Continued.
Product Animal type Stroke model Doseadministration
Duration of
administration Major effects References
Crocin Adult maleWistar rat MCAO
15, 30, 60, and
120mg/kg
intraperitoneally
At the start and 1, 3, and






(2) ↑SOD, GPx, and




(4) ↓MDA level in the
cortex of the brain
tissues.
Crocin Adult maleWistar rat MCAO
50 and 80mg/kg








Crocin Male ddYmice MCAO
10mg/kg
intravenously
Before and 3 hours after
MCAO induction ↓Infarct volume. [49]














hours for 72 hours after
the induction of
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Safranal Adult maleWistar rat MCAO
72.5 and 145mg/kg
intraperitoneally











SD, Sprague-Dawley; MCAO, middle cerebral artery occlusion; BCCAO, bilateral common carotid artery occlusion; GFAP, glial fibrillary acidic protein;
MDA, malondialdehyde; GPx, glutathione peroxidase; NO, nitric oxide; TAC, total antioxidant capacity; VEGF, vascular endothelial growth factor; BNP,
brain natriuretic peptide; BBB, blood-brain barrier; ULK, Unc-51 like autophagy activating kinase; NADPH, nicotinamide adenine dinucleotide phosphate;
MMP, matrix metallopeptidase; SOD, superoxide dismutase.
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the most effective dose of crocin was 60mg/kg and suggested
that higher doses do not have more protective effect. Ad-
ministration of crocin (60mg/kg) 1 hour before, at the start,
or 1 hour after ischemia decreased brain edema by 48%, 52%,
and 51%, respectively. Furthermore, crocin (60mg/kg)
markedly decreased the level of malondialdehyde (MDA)
and enhanced activity of glutathione peroxidase (GPx) and
superoxide dismutase (SOD) in the ischemic cortex [45].
Using an MCAO rat model, Sarshoori et al. explored the
histopathological manifestations of transient focal cerebral
ischemia in response to crocin intraperitoneal injection.
Briefly, Wistar rats were treated by intraperitoneal injection
of 50 and 80mg/kg of crocin at the start of ischemia. A
significant decrease in infarct volume was evident in the
cortex and striatum at the right hemispheres of the crocin
group 24 hours after ischemia. However, 80mg/kg of crocin
exerted a higher efficacy. Another histopathological finding
was that crocin effectively reduced axonal fragmentation,
fiber demyelination, and prenecrotic neurons number in the
ischemic areas. +is study concluded that crocin is sufficient
to suppress ischemia-induced damage by preventing the
alternations of histopathological parameters [46].
Transient global cerebral I/R markedly promoted the
generation of nitric oxide (NO) and the activity of nitric
oxide synthase (NOS). +e reperfusion led to serious edema
with mitochondrial injuries in the cortical microvascular
endothelial cells, as well as increased membrane G protein-
coupled receptor kinase 2 (GRK2) expression, and decreased
cytosol GRK2 expression. Besides, increased phosphoryla-
tion of extracellular signal-regulated kinase1/2 (ERK1/2)
and reduced expression of MMP-9 were detected in cortical
microvessels after I/R (20min/24 h). As well as the positive
control crocin (20mg/kg, 21 days), pretreatment with
Weinaokang, which contains active compounds of Ginkgo,
Ginseng, and saffron, on ischemic injuries (20, 10mg/kg, 21
days) significantly inhibited nitrative injury and modulated
the ultrastructure of cortical microvascular endothelial cells.
Besides, Weinaokang inhibited GRK2 translocation from
cytosol to the membrane (at 20mg/kg) and decreasedMMP-
9 expression and ERK1/2 phosphorylation in cortical
microvessels [47].
Zhang et al. [48] showed that oral administration of crocin
had better effectiveness in cerebral protection than an intra-
venous injection. Crocin and its metabolite crocetin were not
detected in the brain of cerebral I/R rats, indicating a target site
of periphery. After oral administration of crocin instead of
intravenous injection, abundant crocetin was found in plasma.
Indeed, oral administration of crocetin displayed similar ce-
rebral protection to that of crocin, but this effect was not clearly
found by intravenous crocetin administration, representing the
importance of crocetin in gut. Furthermore, orally administered
crocin demonstrated less cerebral-protective effect in pseudo-
germ-free MCAO rats.
Among saffron’s ingredients, crocin was the most ef-
fective in promoting mRNA expression of gamma-gluta-
mylcysteine synthase, which contributes to glutathione
synthesis as the rate-limiting enzyme, and the carotenoid
markedly decreased infarcted areas caused by MCAO in
mice [49].
6. Experimental Studies Conducted on the
Effects of Safranal on Ischemia Stroke
Sadeghnia et al. utilized the rat models of transient MCAO,
which continued by 24 hours of reperfusion. Safranal (72.5
and 145mg/kg) was administrated intraperitoneally by 0, 3,
and 6 hours after reperfusion. Compared with the control
animals, the level of MDA significantly decreased in safranal
groups, while total sulfhydryl (SH) and antioxidant power
showed a considerable increase. +e percentages of
degenerated hippocampal cells, mean infarct volume, and
neurological deficits were reduced with both doses of
safranal. Collectively, safranal exerted an explicit neuro-
protective effect on transient focal cerebral ischemia [50].
One study showed that administration of safranal increased
the total SH contents and antioxidant capacity in hippo-
campus of rats with transient global cerebral ischemia.
Besides, administration of safranal reduced theMDA level in
hippocampus of rats with transient global cerebral ischemia
[51].
In a recent study by Forouzanfar et al. [52], oxygen-
glucose deprivation exposure decreased the cell viability and
enhanced intracellular ROS production, apoptosis, and
oxidative DNA damage, in comparison with untreated
control PC12 cells. Pretreatment with safranal (40 and
160 μM) markedly attenuated cell death, apoptosis, and
oxidative damage induced by oxygen-glucose deprivation in
PC12 cells. Additionally, safranal significantly decreased the
overexpression of Bax/Bcl-2 ratio and active caspase-3 fol-
lowing oxygen-glucose deprivation.
7. Human Studies Conducted on the Effects of
Saffron on Ischemia Stroke
Fifty ischemic stroke patients with specific severity of
symptoms at admission (National Institute of Health Stroke
Scale (NIHSS) score� 5–20) and less than 24 h since the
onset of stroke were randomly assigned to receive either
routine stroke care (control group) or routine care plus
aqueous extract of saffron capsule (200mg/day) (saffron
group). Patients in both groups were monitored for the
study days including four days of hospital stay and the
following three months. In saffron group, the severity of
stroke during the first four days was reduced compared to
the control group. Compared to the concentrations on the
first day, serum neuron specific enolase and s100 levels were
markedly reduced and brain-derived neurotrophic factor
(BDNF) level was enhanced in the saffron group on the
fourth day. At the end of the three-month follow-up period,
the mean Barthel index was markedly higher in the saffron
group compared to the control group [53].
A recent study has been conducted to evaluate the role of
aqueous extract of saffron in decreasing oxidative stress
among patients with ischemic stroke. Forty ischemic stroke
patients with NIHSS score� 5–20 less than 24 h since the
onset of stroke were randomly divided into two groups:
control group and saffron group. +e patients in control
group received routine stroke care and the patients in saffron
group received routine care plus capsule of saffron 400mg/
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day (200mg twice daily) over a period of four days. On the
fourth day after the onset of ischemic stroke, the saffron-
treated group had higher levels of antioxidant enzymes
activities and GSH and TAC levels than the control group,
while MDA concentration was lower. Furthermore, the
severity of stroke was markedly decreased after 4 days in the
saffron-treated group. +e severity of stroke was negatively
associated with the GSH and TAC concentrations and
positively associated with the MDA concentration [54].
8. Possible Mechanism of Neuroprotective
Potency of Saffron and Its Ingredients in
Ischemia Stroke
Several investigations attempted to clarify the mechanisms
underlying the neuroprotective function of saffron and its
active derivatives in ischemia stroke. Oxidative stress is
caused by an imbalance between prooxidants and antioxi-
dants, resulting in overproduction of ROS. ROS are biphasic
and are involved in natural physiological processes as well as
in a number of disease processes, thereby mediating damage
to cellular structures such as lipids, membranes, proteins,
and DNA [55, 56]. +e cerebral vasculature is a main target
of oxidative stress which plays a major role in the patho-
genesis of ischemic brain injury after cerebrovascular attack
[55, 56]. Consequently, oxidative stress contributes directly
to necrosis and apoptosis via a number of pathways in is-
chemic tissue [57, 58]. Previous studies showed that saffron
exhibited a potential antioxidant and antiapoptotic property,
which is attributed to the bioactive ingredients of saffron
[40, 50, 59]. Brain edema, as a result of ischemic stroke,
could be attributed to the elevated brain natriuretic peptide
(BNP) level [60]. Saffron has exhibited a substantial effect on
decreasing BNP in brain of I/R rats. It is suggested that
saffron-induced BNP lowering may be due to its antioxidant
properties [40].
Recently, it has been reported that saffron effectively
enhanced the expression of VEGF in ischemic boundary
zone, which plays a critical role in cerebral protection after I/
R injuries [40]. Indeed, VEGF confers neuroprotection and
promotes neurogenesis and cerebral angiogenesis [61]. Brain
ischemia leads to an acute and prolonged inflammatory
process, characterized by rapid activation of resident cells
(mainly microglia), production of proinflammatory medi-
ators, and infiltration of numerous types of inflammatory
cells (including neutrophils, different subtypes of T cells,
monocyte/macrophages, and other cells) into the ischemic
brain tissue [62, 63]. Recent experiment has found that
saffron could attenuate inflammation in the ischemic brain
[20, 42].
9. Conclusion
Collectively, the data from the referred experiments provide
insight into the beneficial effect of saffron and its derivatives,
particularly safranal and crocin, against neural injuries in the
cerebral ischemia. +e studies indicated that administration
of saffron or its ingredients could make a notable contri-
bution to the prevention of histopathological alternation as
well as improvement of neurological deficit. However,
several investigations have noted that the downregulation of
apoptosis, inflammation, and autophagy, alleviation of glial
scar formation, prevention of oxidative stress, and reduction
of brain edema are among the most mentioned mechanisms
mediating the saffron efficacy. +us, saffron and its active
constituents can be a candidate as therapeutic agent, either
alone or in a combined form, with current strategies for
ischemia stroke treatment.
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